Array nails $10M milestone; Clinical Data asset sale spurs pharma transition

 @FierceBiotech: GSK's Witty calls for an R&D renaissance. Story | Follow @FierceBiotech

 @JohnCFierce: Basilea awarded $130M from J&J after the pharma company dumped their antibiotic pact--after the trials were messed up. Report | Follow @JohnCFierce

> Array BioPharma says it scored a $10 million milestone in its three-year-old pact with Celgene. Array anticipates initiating a Phase I dose escalation trial in cancer patients with ARRY-382, a small molecule cFMS inhibitor, during the first quarter of 2011. Release

Special Report: The most (and least) efficient Big Pharma companies. Report

> Clinical Data has struck a deal to sell its genetic and pharmacogenomic testing and biomarker development business to Transgenomic for $15.4 million. The deal clears the way for Clinical Data to transition into a pharma company with the expected launch of vilazodone. Story

> ImmunoGen has initiated a randomized Phase I/II clinical trial to evaluate its proprietary product candidate, IMGN901 (lorvotuzumab mertansine), for first-line treatment of small-cell lung cancer in patients with extensive disease. Release

> The Scripps Research Institute and Aileron Therapeutics have forged a pact that will add Scripps Research's "Click" chemistry to Aileron's proprietary stabilized peptide and protein technology platforms, which includes the Stapled Peptide technology. Release

Special Report: The fastest growing therapeutic classes. Chart

> Shares of Angiotech Pharmaceuticals surged on the news that it has entered into a private label product supply agreement with Hologic for soft tissue biopsy instruments manufactured by Angiotech. Release

And Finally... A Canadian biotech company has developed an apple that doesn't start to brown right after you slice it, saying that the new, new apple should make for a better product on supermarket shelves. Story

Suggested Articles

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

The trial linked RG6346 to reductions in hepatitis B surface antigen that suggest the RNAi therapy can hold its own against drugs from J&J and Vir.